Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* patients scheduled for bunion surgery~Exclusion Criteria:~* daily opioid use~* drug or alcohol abuse~* pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Sufentanil NanoTab 20 mcg (Type: EXPERIMENTAL): Sufentanil NanoTab 20 mcg as needed every 60 minutes for 12 hours
- Sufentanil NanoTab 30 mcg (Type: EXPERIMENTAL): Sufentanil NanoTab 30 mcg as needed every 60 minutes for 12 hours
- Placebo NanoTab (Type: PLACEBO_COMPARATOR): Placebo NanoTab as needed every 60 minutes for 12 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).